Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Gastric Cancer: early-phase trial registry
72 of 159 indexed Gastric Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #69 of 28,707 conditions by registered trial count.
159 US clinical trials · 72 currently recruiting · #69 of 28,707 conditions by registered trial count
Gastric Cancer: 159 US clinical trials tracked, 72 recruiting.
Gastric Cancer is the subject of 159 registered US clinical trials on ClinicalTrials.gov, 72 of them currently open to new participants. 17 are in Phase 3-4 (later-stage) and 118 in Phase 1-2 (earlier-stage). The most active sponsor is AstraZeneca, running 11 of these trials.
Enrollment posture brief
Registry condition gastric-cancer
OPEN 72 | RECR 45% | LATE 17 | EARLY 118 | RANK #69 | SPON 11
Volume-matched condition peers
Nearest open-share peer: Non-Small Cell Lung Cancer (45% recruiting · 455 trials)
Gastric Cancer lists 72 open slots (45% of 159 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Gastric Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Gastric Cancer is recruiting above its size-band peers.
72 of 159 indexed trials (45.3%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Gastric Cancer trials is spread across many organizations.
AstraZeneca accounts for 11 of 159 trials (6.9%). 107 distinct sponsors appear on at least one study for this condition label.
-
Typical Gastric Cancer enrolment sits around 117 participants.
Median target enrolment is 117 among the 154 trials that report a genuine target (sentinel values excluded). 65 of those (42.2%) plan for fewer than 100 participants.
-
Gastric Cancer research is mostly interventional.
142 interventional and 17 observational studies make up this index (89.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
159 total, page 1 of 4
Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples From Colorectal Cancer Patients
Vanderbilt University Medical Center
NCT00899626
A Study Collecting Health Information to Understand and Prevent Gastric Cancer
Memorial Sloan Kettering Cancer Center
NCT06370143
EsophaCap for the Detection of Early Esophageal Carcinoma
Johns Hopkins University
NCT04214119
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
AstraZeneca
NCT07431281
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Daiichi Sankyo
NCT06172478
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
Daiichi Sankyo
NCT06731478
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT05208762
Comprehensive Outcomes for After Cancer Health
Pack Health
NCT05349227
Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers
University of Missouri-Columbia
NCT02838836
The GAstric Precancerous Conditions Study
Stanford University
NCT04191551
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
AstraZeneca
NCT06346392
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
Shanghai Henlius Biotech
NCT06532006
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Merus B.V.
NCT03526835
The Gastric Cancer Foundation: A Gastric Cancer Registry
Stanford University
NCT01514045
Detection of Minimal Residual Disease Using Exosomal miRNA Distant Metastasis Markers
City of Hope Medical Center
NCT07243015
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Apollomics
NCT03175224
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
AstraZeneca
NCT05489211
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
AstraZeneca
NCT04379596
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech
NCT05581004
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
ArriVent BioPharma
NCT07066657
Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis
National Cancer Institute (NCI)
NCT04557969
A Study of NX-1607 in Adults With Advanced Malignancies
Nurix Therapeutics
NCT05107674
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
I-Mab Biopharma US Limited
NCT04900818
Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow
University of Missouri-Columbia
NCT03551951
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
National Cancer Institute (NCI)
NCT06503146
Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)
University of California, Davis
NCT06101277
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
AstraZeneca
NCT06005493
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
SystImmune
NCT06293898
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
SillaJen
NCT05768932
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
BeiGene
NCT06257264
Resilience and Equity in Aging, Cancer, and Health (REACH)
Dana-Farber Cancer Institute
NCT04674267
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
EMD Serono Research & Development Institute
NCT06710132
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
Udai Kammula
NCT03935893
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
AstraZeneca
NCT06219941
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
Sutro Biopharma
NCT07227168
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Jazz Pharmaceuticals
NCT06695845
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
I-Mab Biopharma US Limited
NCT07432295
IKS014 in Advanced Solid Tumors That Express HER2
Iksuda Therapeutics
NCT05872295
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
AstraZeneca
NCT05702229
Molecular and Epidemiological Risk Factors in the Development of Gastric Cancer
The University of Texas Health Science Center at San Antonio
NCT04600466
A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer
Toray Industries
NCT06038578
A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy
Chimeric Therapeutics
NCT06055439
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies
NCT06047379
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
MOMA Therapeutics
NCT06974110
Study for AZD4360 in Participants With Advanced Solid Tumours
AstraZeneca
NCT06921928
Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
Anwaar Saeed
NCT03539822
A Beta-only IL-2 ImmunoTherapY Study
Medicenna Therapeutics
NCT05086692
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
ModeX Therapeutics, An OPKO Health Company
NCT06239194
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Perspective Therapeutics
NCT06710756
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
National Cancer Institute (NCI)
NCT03190941
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 69 |
| Phase 2 | 49 |
| Phase 3 | 13 |
| Phase 4 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Gastric Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Gastric Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Gastric Cancer page
159 registered trials, 72 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 72 Gastric Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- AstraZeneca sponsors the most Gastric Cancer trials on record, review their full trial history before evaluating a specific study. See AstraZeneca's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Gastric Cancer condition card totals 159 registered trials; most-linked intervention Paclitaxel; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.